Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Other Accumulated Expenses: 2019-2023

Historic Other Accumulated Expenses for Pharming Group N.V (PHAR) over the last 1 years, with Jun 2023 value amounting to -$1.7 million.

  • Pharming Group N.V's Other Accumulated Expenses was N/A to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$1.7 million, marking a year-over-year change of. This contributed to the annual value of -$1.1 million for FY2021, which is 67264.53% down from last year.
  • As of Q2 2023, Pharming Group N.V's Other Accumulated Expenses stood at -$1.7 million, which was down 59.32% from -$1.1 million recorded in Q4 2021.
  • Over the past 5 years, Pharming Group N.V's Other Accumulated Expenses peaked at $2.5 million during Q3 2020, and registered a low of -$1.7 million during Q2 2023.
  • In the last 2 years, Pharming Group N.V's Other Accumulated Expenses had a median value of -$1,094 in 2021 and averaged -$467,419.
  • As far as peak fluctuations go, Pharming Group N.V's Other Accumulated Expenses soared by 96.31% in 2020, and later tumbled by 67,264.53% in 2021.
  • Pharming Group N.V's Other Accumulated Expenses (Quarterly) stood at -$44,000 in 2019, then soared by 96.31% to -$1,624 in 2020, then plummeted by 67,264.53% to -$1.1 million in 2021, then reached -$1.7 million in 2023.
  • Its Other Accumulated Expenses stands at -$1.7 million for Q2 2023, versus -$1.1 million for Q4 2021 and $272,000 for Q3 2021.